Increasing Cancer Incidence Fueling The Growth Of The Market Due To Rising Prevalence Of Unhealthy Lifestyle Habits Is Supporting Development Across The Oncology Clinical Trials Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The Oncology Clinical Trials Market Between 2026 And 2030?

The size of the oncology clinical trials market has experienced strong expansion in recent years. It is forecast to increase from $14.99 billion in 2025 to $15.98 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.6%. The historical growth of this market can be attributed to factors such as limited treatment options for cancer patients, a global increase in cancer incidence, rising pharmaceutical and biotech research and development investments, a growing number of academic clinical research centers, and enhanced awareness of the importance of clinical trials.

The oncology clinical trials market is anticipated to exhibit substantial growth in the upcoming years. It is projected to expand to $20.4 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 6.3%. This expansion during the forecast period can be attributed to the evolution of personalized oncology treatments, the proliferation of multicenter and global studies, the adoption of digital tools for patient monitoring, the integration of AI and big data into trial design, and increased government and private sector investment in oncology research. Significant trends expected during the forecast period include the widening scope of immunotherapy and targeted therapy clinical trials, a growing emphasis on multicenter and randomized controlled trials, enhanced investment in post-marketing surveillance and long-term safety evaluations, the increasing embrace of cell and gene therapy trials, and the incorporation of biomarker and pharmacogenomics studies into oncology research.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27371&type=smp

Which Significant Factors Are Encouraging Growth In The Oncology Clinical Trials Market?

The rising occurrence of cancer is anticipated to drive the expansion of the oncology clinical trials market moving forward. Cancer incidence defines the count of new cancer diagnoses within a specific population over a set period. This increase in cancer cases primarily results from unhealthy lifestyle habits, including poor diet, physical inactivity, tobacco use, and excessive alcohol consumption, which elevate the risk of developing various cancers. Oncology clinical trials advance cancer treatment by evaluating new therapies and interventions, thereby improving patient outcomes through evidence-based research. These trials also accelerate medical innovation by testing the safety and efficacy of treatments, fostering progress in cancer prevention, diagnosis, and care. For instance, data from October 2025, as reported by the National Health Service (NHS), a UK-based government health agency, indicated 354,820 new cancer diagnoses in 2023, averaging 972 per day, which was 8,605 more than in 2022. Consequently, the growing cancer incidence is a key factor propelling the growth of oncology clinical trials.

Which Segment Groups Define The Oncology Clinical Trials Market Landscape?

The oncology clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Study Design: Interventional, Observational, Expanded Access

3) By Therapeutic Modality: Immunotherapy, Targeted Therapy, Chemotherapy, Cell And Gene Therapy, Other Therapeutic Modalities

4) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Other Indications

5) By Sponsor Type: Pharmaceutical And Biotech Companies, Academic And Research Institutes, Government Organizations, Other Sponsor Types

Subsegments:

1) By Phase I: Safety And Dosage Studies, Pharmacokinetics And Pharmacodynamics Studies, Biomarker Identification Studies

2) By Phase II: Efficacy And Side Effects Studies, Dose-Response Relationship Studies, Therapeutic Effectiveness Studies

3) By Phase III: Large-Scale Efficacy Studies, Comparative Effectiveness Studies, Multicenter Randomized Controlled Trials

4) By Phase IV: Post Marketing Surveillance Studies, Long-Term Safety Studies, Quality Of Life Studies

What Trends Are Affecting The Oncology Clinical Trials Market Dynamics?

Leading companies in the oncology clinical trials market are focusing on developing technologically advanced solutions, such as advanced bioinformatics platforms, to improve data analysis, expedite patient recruitment, and optimize trial outcomes. These advanced bioinformatics platforms are sophisticated software systems that utilize computational tools and algorithms to gather, analyze, and interpret complex biological and clinical data for research and healthcare applications. For instance, in September 2023, Deep 6 AI, a US-based healthcare technology company, introduced an AI-powered genomics module designed to speed up enrollment in precision medicine and oncology clinical trials. This module employs artificial intelligence and natural language processing to extract both structured and unstructured genomics data from electronic medical records, enabling the real-time identification and precise matching of patients with specific genetic markers. It offers researchers the capability to search millions of records for more than 19,000 genes and 30,000 mutation names, significantly accelerating patient recruitment and enhancing the efficiency of clinical trial design.

Who Are The Key Market Participants In The Oncology Clinical Trials Market?

Major companies operating in the oncology clinical trials market are Pfizer Inc., Johnson & Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Genentech Inc., BeiGene Ltd., Seagen Inc.

Access The Complete Oncology Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-clinical-trials-global-market-report

Which Region Is The Primary Market For The Oncology Clinical Trials Market?

North America was the largest region in the oncology clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Oncology Clinical Trials Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=27371&type=smp

Browse Through More Reports Similar to the Global Oncology Clinical Trials Market 2026, By The Business Research Company

Concrete Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/concrete-materials-global-market-report

Decorative Concrete Market Report 2026

https://www.thebusinessresearchcompany.com/report/decorative-concrete-global-market-report

Cellular Concrete Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellular-concrete-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795